全文获取类型
收费全文 | 70480篇 |
免费 | 6314篇 |
国内免费 | 3185篇 |
学科分类
医药卫生 | 79979篇 |
出版年
2023年 | 756篇 |
2022年 | 1291篇 |
2021年 | 2154篇 |
2020年 | 2179篇 |
2019年 | 2398篇 |
2018年 | 2287篇 |
2017年 | 2250篇 |
2016年 | 2615篇 |
2015年 | 2887篇 |
2014年 | 4696篇 |
2013年 | 4897篇 |
2012年 | 4823篇 |
2011年 | 5143篇 |
2010年 | 4161篇 |
2009年 | 3951篇 |
2008年 | 3905篇 |
2007年 | 3814篇 |
2006年 | 3466篇 |
2005年 | 2958篇 |
2004年 | 2455篇 |
2003年 | 2125篇 |
2002年 | 1725篇 |
2001年 | 1517篇 |
2000年 | 1171篇 |
1999年 | 996篇 |
1998年 | 831篇 |
1997年 | 718篇 |
1996年 | 561篇 |
1995年 | 667篇 |
1994年 | 573篇 |
1993年 | 467篇 |
1992年 | 444篇 |
1991年 | 350篇 |
1990年 | 319篇 |
1989年 | 286篇 |
1988年 | 238篇 |
1987年 | 206篇 |
1986年 | 170篇 |
1985年 | 445篇 |
1984年 | 464篇 |
1983年 | 375篇 |
1982年 | 379篇 |
1981年 | 316篇 |
1980年 | 290篇 |
1979年 | 261篇 |
1978年 | 206篇 |
1977年 | 159篇 |
1976年 | 177篇 |
1975年 | 154篇 |
1974年 | 126篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Si Jiang Upasana Manandhar Kai P. Zheng Qin Liu Pin Liang Ji Q. Song 《Journal of cutaneous pathology》2019,46(10):769-774
Hypersensitivity to mosquito bites (HMB) refers to skin reactions such as bullae and necrosis, which occurs after being bitten by mosquitoes and can present with multiple systemic reactions such as fever, lymphadenopathy, hepatosplenomegaly simultaneously or subsequently. A 48‐year‐old male patient presented with recurrent erythema, nodules, papules, vesicles and bullae over upper body and bilateral limbs with itching over the sites of mosquito bite for more than 1 year with low‐grade fever and superficial lymph nodes enlargement. The patient's symptoms failed to improve from conventional anti allergic treatment although skin biopsy showed changes of HMB reaction. Subsequently, the lymph node was biopsied and was reported to be nodal marginal zone lymphoma (NMZL), and then the patient was eventually diagnosed with nodal marginal zone lymphoma with HMB. To date only one case of nodal marginal zone lymphoma with HMB has been reported from Korea, and this is the first case to be reported in China. 相似文献
63.
64.
65.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
66.
目的:探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对初治前弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者预后的意义。方法:回顾性分析2010年1月至2019年10月,新疆医科大学附属肿瘤医院收治的165例初治DLBCL患者,确定了NLR(>2.77)在预后预测中的最佳临界值,采用Log-rank检验和Cox回归模型进行分析,评价治疗前NLR对无进展生存期(progression free survival time,PFS)和总生存期(overall survival rate,OS)的影响。结果:在入选的165例患者中,有67例患者治疗前NLR升高(>2.77),NLR升高与PFS和OS较短的患者明显相关(P<0.001和P=0.003)。多变量分析进一步表明,NLR>2.77是PFS的独立预测因子。结论:治疗前NLR升高提示DLBCL患者预后不良。 相似文献
67.
68.
Bipul Gnyawali Antoinette Pusateri Ashley Nickerson Sajid Jalil Khalid Mumtaz 《World journal of gastroenterology : WJG》2022,28(29):3793-3802
Chronic Hepatitis B is a highly prevalent disease worldwide and is estimated to cause more than 800000 annual deaths from complications such as cirrhosis and hepatocellular carcinoma (HCC). Although universal hepatitis B vaccination programs may have reduced the incidence and prevalence of chronic hepatitis B and related HCC, the disease still imposes a significant healthcare burden in many endemic regions such as Africa and the Asia-Pacific region. This is especially concerning given the global underdiagnosis of hepatitis B and the limited availability of vaccination, screening, and treatment in low-resource regions. Demographics including male gender, older age, ethnicity, and geo graphic location as well as low socioeconomic status are more heavily impacted by chronic hepatitis B and related HCC. Methods to mitigate this impact include increasing screening in high-risk groups according to national guidelines, increasing awareness and health literacy in vulnerable populations, and developing more robust vaccination programs in under-served regions. 相似文献
69.
《Vaccine》2022,40(6):924-933
The European Clinical Trial Regulation No 536/2014 is the first mandate for a non-technical, publicly disclosed, plain language summary (PLS) of clinical trial results. This easy-to-understand summary has the potential to inform the public about clinical trial results and thereby improve health literacy in vaccines.To investigate the utility of the PLS, we undertook 2 online surveys (July/October 2020) in the United Kingdom, the United States and India. Participants were selected by quota sampling to ensure representation of gender, age and parental status. Those lacking interest in vaccine clinical research were excluded. In survey 1, participants were questioned about their interest in and expectations of vaccine trial results. In survey 2, the perceptions of participants to a range of written communication styles used in publicly available PLSs were evaluated.A total of 66 (13%) and 122 (29%) individuals were excluded solely due to lack of interest in vaccine clinical research in surveys 1 and 2, respectively; 450 respondents (150/country) completed survey 1 and 300 (100/country) completed survey 2. In survey 1, there was a correlation (p < 0.01) between claimed knowledge of and trust in vaccines. Healthcare professionals were the most trusted source for vaccine information, while vaccine companies were ranked relatively low. In survey 2, infographic PLS formats were considered easiest to understand, most engaging and the strongest communicators. Emphasizing the main points of the infographics in the text did not improve comprehension or recall. Most respondents (86%) indicated that they would like to see this type of communication in the future.Overall, this research suggests that the PLS, by optimizing content and format, has a potential to increase health literacy, and thereby, as part of a wider integrated communication strategy, build vaccine knowledge and confidence. 相似文献
70.
《Vaccine》2022,40(12):1872-1878
BackgroundThe MenB-FHbp vaccine (Trumenba®) is licensed in various countries for the prevention of meningococcal serogroup B disease in individuals ≥ 10 years of age. The clinical development program included 11 completed trials where, in each trial, MenB-FHbp had an acceptable safety profile after a primary vaccination series was administered to individuals 10–65 years of age. However, the detection of potential rare events was limited because of individual clinical trial size. The current safety analysis evaluates pooled reactogenicity and other adverse events (AEs) reported in these trials to identify new safety signals not detectable in individual trials.MethodsEleven trials contributed safety data, of which 10 recorded local and systemic reactogenicity events; 8 of the trials were controlled, and reactogenicity data were pooled for 7 of these 8 trials. Additional AE evaluations included immediate AEs (IAEs), medically attended AEs (MAEs), serious AEs (SAEs), newly diagnosed chronic medical conditions (NDCMCs), and autoimmune or neuroinflammatory conditions.ResultsLocal and systemic reactions were more frequent in the MenB-FHbp group (n = 15,294) compared with controls (n = 5509), although most reactions were transient and mild to moderate in severity. Frequencies of IAEs, SAEs, MAEs, NDCMCs, and autoimmune or neuroinflammatory conditions were similar between the MenB-FHbp and control groups.ConclusionsMenB-FHbp demonstrated a favorable safety and tolerability profile in the clinical development program of > 15,000 vaccine recipients ≥ 10 years of age. No new safety signals were identified in the pooled analysis compared with data from the individual trials. Continued postmarketing safety surveillance is important for the identification of rare events.Clinicaltrials.gov: NCT01299480; NCT000808028; NCT00879814; NCT00780806; NCT01352845; NCT01352793; NCT01461993; NCT01323270; NCT01830855; NCT01461980; NCT01768117. 相似文献